News room - Egetis Therapeutics

1 December, 2023 Save the Date: Egetis to host Investor Day on December 19, 2023 News Corporate Information Other Corporate Information English IR Optional

10 November, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan News Corporate Action Other English Regulatory MAR IR Optional

8 November, 2023 Interim report Q3 2023 News English Regulatory MAR Report Interim Q3 IR Optional

7 November, 2023 Egetis Therapeutics has resolved on directed issues of warrants and a convertible bond within the framework of the drawdown of Tranche A of the previously communicated debt financing News Corporate Action Shares Issuance English Regulatory Listing Regulation IR Optional

7 November, 2023 Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs News Corporate Information Staff change English IR Optional

1 November, 2023 Egetis’ Nomination Committee for the 2024 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional

31 October, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional

27 October, 2023 Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional

11 October, 2023 Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory LHFI IR Optional

10 October, 2023 Egetis Therapeutics has secured approximately SEK 462 million in a combined financing comprising a SEK 172 million equity private placement and SEK 290 million debt financing News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer

9 October, 2023 Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency News Corporate Information Other Corporate Information English IR Optional

25 September, 2023 ReTRIACt trial design presented at the Annual Meeting of the European Society for Paediatric Endocrinology News Corporate Information Other Corporate Information English IR Optional

12 September, 2023 Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional

30 August, 2023 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional

22 August, 2023 Interim report Q2 2023 News English Regulatory MAR VPML Report Interim Q2 IR Optional

24 July, 2023 Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial News Corporate Information Other Corporate Information English IR Optional

28 June, 2023 Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

16 June, 2023 Board directors in Egetis Therapeutics acquire shares News Corporate Information Other Corporate Information English IR Optional

31 May, 2023 Board director in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional

23 May, 2023 Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

27 April, 2023 Bulletin from Egetis Therapeutics’ Annual General Meeting 2023 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

26 April, 2023 Interim report January-March 2023 News English Regulatory MAR Report Interim Q1 IR Optional

30 March, 2023 Egetis comments on market rumors News Corporate Action M&A English Regulatory MAR IR Optional

28 March, 2023 Egetis Therapeutics’ 2022 annual report published News English Regulatory VPML Report Annual IR Optional

24 March, 2023 Egetis continues to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional

Press releases

2023

Calendar and upcoming reports

Contact us

Press releases

2023

Calendar and upcoming reports

Subscribe

Contact us